𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Alzheimer vaccine: amyloid-β on trial

✍ Scribed by Stephen R. Robinson; Glenda M. Bishop; Gerald Münch

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
106 KB
Volume
25
Category
Article
ISSN
0265-9247

No coin nor oath required. For personal study only.

✦ Synopsis

A new therapeutic approach is being developed for the treatment of Alzheimer's disease (AD). This approach involves the deliberate induction of an autoimmune response to amyloid-beta (Abeta) peptide, the constituent of neuritic plaques that is thought to cause the neurodegeneration and dementia in AD. If this approach is to be effective, antibodies must be produced that can selectively target the toxic forms of Abeta, while leaving the functionally-relevant forms of Abeta and its precursor protein untouched. Furthermore, an approach needs to be found that avoids provoking an acute neuroinflammatory response. The situation is made even more challenging by uncertainty regarding which isoforms of Abeta contribute to the pathogenesis of AD.

📜 SIMILAR VOLUMES

Ill-fated amyloid-β vaccine
Ill-fated amyloid-β vaccine
✍ Mark A. Smith; Craig S. Atwood; James A. Joseph; George Perry 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 28 KB

The premature suspension of the amyloid-␤ vaccine for the treatment of Alzheimer disease (AD), while disappointing, is not surprising. Amyloid-␤ serves a key role in redox homeostasis (Nunomura et al., 2001) and its removal, by vaccination (or others) strategies, would be predicted to increase oxida

Alzheimer's disease: β-Amyloid protein a
Alzheimer's disease: β-Amyloid protein and tau
✍ Maho Morishima-Kawashima; Yasuo Ihara 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

## Abstract Research on the molecular pathogenesis of Alzheimer's disease (AD) has made great strides over the last decade. This progress is the result of protein chemical analysis of two extracellular and intracellular fibrillary lesions in AD brain conducted during the 1980s, which identified β‐a

Polypeptide conjugates comprising a β-am
Polypeptide conjugates comprising a β-amyloid plaque-specific epitope as new vaccine structures against Alzheimer's disease
✍ Marilena Manea; Gábor Mezö; Ferenc Hudecz; Michael Przybylski 📂 Article 📅 2004 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 243 KB

## Abstract Immunotherapeutic approaches designed to induce a humoral immune response have recently been developed for possible vaccination to the treatment of Alzheimer's disease (AD). Based on the identification of Aβ(4–10) (FRHDSGY) as the predominant B‐cell epitope recognized by therapeutically